![](https://exumabio.com/wp-content/uploads/2017/12/pac-bio-sequel.jpg)
An unbiased, data-driven approach to CAR development
We leverage our immunology-inspired libraries and analytics to develop cell and gene therapies that are rooted in science and benchmarked against best-in-class molecules. Our innovative, in-house libraries are screened for the best CAR construct for a given target indication, guided by automated analyses of large datasets. Developing the candidate diversity necessary to take data-driven risks delivers multiple “shots-on-goal” while carrying common learnings from product to product.
![](https://exumabio.com/wp-content/uploads/2017/12/monitoring_darwinian_evolution_2.jpg)
Monitoring Darwinian evolution through molecular genetics to find the best CARs
Our infrastructure, data transfer platform, and analytics capabilities allow us to cast a wider net to find the best CAR attributes. Our approach has three key advantages:
- Providing sufficient library diversity in the final product configuration
- Using biologically relevant cell types, e.g. primary human cells, instead of immortalized cell line models
- Applying physiologically relevant screens instead of artificial environments
When applied through our big data analytics platform, this allows us to find rare events with significantly improved attributes.